Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes.
Dr. Joshua Logan, DC, BCN, founder of True North Health Center, explains neuropathy, a condition affecting millions. It is not a disease but results from issues like diabetes, chemotherapy, or trauma.
Data from continuous glucose monitors can predict nerve, eye and kidney damage caused by type 1 diabetes researchers have found. That suggests doctors may be able to use data from the devices to help ...